Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Researchers from the Regenstrief Institute and the Indiana University Center for Aging Research have identified the first biomarker that appears to be linked to the duration of delirium. This novel role for S100ß as a biomarker for delirium duration in critically ill patients may have important implications for refining future delirium treatment in intensive care unit patients.
Delirium in older adults is associated with increased probability of developing dementia and to a high death rate. Duration of delirium in the ICU has been identified as an independent predictor of mortality.
S100β, or S100 calcium binding protein B, has previously been identified as a marker associated with delirium, but this is the first study to link it to the duration of delirium in critically ill patients. It is estimated that each year more than 7 million hospitalized Americans suffer from the acute confusion and disorientation characteristic of delirium and about half of mechanically ventilated patients in the ICU develop delirium.
The study, published online this month in the peer-reviewed open access International Journal of General Medicine, found that ICU patients with abnormally elevated levels of S100β either on day 1 or day 8, or both, had higher delirium duration compared to patients with normal S100β levels on both days.
"Using the biomarker to identify patients with a predisposition toward longer delirium duration should be useful in instituting more effective and personalized clinical therapies, with the end goal of decreasing the burden of delirium for both the patient and the health care system," said Regenstrief Institute investigator and IU Center for Aging Research scientist Babar Ali Khan, M.D., who led the study.
"Utilizing a simple blood test presents an easy and real opportunity to decrease the burden of the syndrome and thereby diminish progression to cognitive impairment in older adults," he said. "Since every day with delirium in the ICU is associated with a 10 percent increased likelihood of death, it's critical to diminish its duration and ultimately prevent it."
Adjusting for age, gender, race and other medical conditions, hospitalized patients with delirium have stays that are more than twice as long; have a greater probability of being discharged to a long-term-care facility; and have a much higher probability of developing dementia than patients who do not experience delirium, according to the American Delirium Society.
Strategies to prevent delirium or decrease delirium duration include waking and conducting "breathing drills" for ventilated patients as well as promoting early mobility and exercise while in the ICU, according to Dr. Khan, a pulmonologist and ICU physician who is an assistant professor of medicine at the IU School of Medicine and medical director of the Eskenazi Health Critical Care Recovery Center.
The research more clearly establishes the S-100 biomarker as an index of the duration of delirium and suggests one possible mechanism that leads to higher delirium duration. It is thought that the biomarker reflects the degree of injury to non-neuronal support (i.e., glial) cells in the brain caused by inflammation, and specifically indexes the activation of glial cells called astrocytes.
This work was supported by grants from the National Institute on Aging (R01AG034205 and K23-AG043476) and National Institute of Mental Health (R24MH080827), both part of the National Institutes of Health. The research was also assisted by the NIH-supported Indiana Clinical and Translational Sciences Institute. The content of the study is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
S100 calcium binding protein B as a biomarker of delirium duration in the intensive care unit – an exploratory analysis, Khan BA, Farber MO, Campbell N, Perkins A, Prasad NK, Hui SL, Miller DK, Calvo-Ayala E, Buckley JD, Ionescu R, Shekhar A, Ely EW, Boustani MA, International Journal of General Medicine - doi.org/10.2147/IJGM.S51004
Indiana University School of Medicine
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Alzheimer's / Dementia category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Indiana University School of Medicine. "Regenstrief and IU investigators identify first biomarker linked to delirium duration." Medical News Today. MediLexicon, Intl., 18 Dec. 2013. Web.
8 Mar. 2014. <http://www.medicalnewstoday.com/releases/270306>
Indiana University School of Medicine. (2013, December 18). "Regenstrief and IU investigators identify first biomarker linked to delirium duration." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/270306.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.